Priming effect with G-CSF enhances in vitro apoptosis by treatment with Ara-c and VP-16 in leukemic cell line

被引：0
|
作者：
Kitagawa, Jun-Ichi [1 ]
Hara, Takeshi [1 ]
Tsurumi, Hisashi [1 ]
Kanemura, Nobuhiro [1 ]
Shimizu, Masahito [1 ]
Moriwai, Hisataka [1 ]
机构：
[1] Gifu Univ, Grad Sch Med, Dept Internal Med 1, Gifu, Japan
来源：
BLOOD | 2007年 / 110卷 / 11期
关键词：
D O I：
10.1182/blood.V110.11.4333.4333
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4333
引用
收藏
页码：151B / 151B
页数：1
相关论文
共 50 条
  • [41] In Vitro Effect Of VPA Together With ATRA and Ara-C On Proliferation and Viability Of Pediatric AML Cell Line THP-1
    Anak, Sema
    Kanbay, Ayca Gul
    Gulec, Cagri
    BLOOD, 2013, 122 (21)
  • [42] Phase II trial of idarubicin, fludarabine, Ara-C, and filgrastim filgrastim (G-CSF) (Ida-FLAG) for treatment of poor prognosis acute myeloid leukemia (AML).
    Wickramanayake, PD
    Steinmetz, HT
    Katay, I
    Glasmacher, A
    Staib, P
    Diehl, V
    BLOOD, 1995, 86 (10) : 3009 - 3009
  • [43] Phase II study of intensive CEV (carboplatin, epirubicin and VP-16) plus G-CSF (granulocyte-colony stimulating factor) in extensive small cell lung cancer
    Gridelli, C
    Perrone, F
    DAprile, M
    Rossi, A
    Palmeri, S
    Curcio, C
    Veltri, E
    Ianniello, G
    Lorusso, V
    Palmieri, G
    Rinaldi, L
    DePlacido, S
    Gallo, C
    Bianco, AR
    EUROPEAN JOURNAL OF CANCER, 1995, 31A (13-14) : 2424 - 2426
  • [44] Dexamethasone, high-dose ara-c, cisplatin and G-CSF (DHAP) prior to intensive therapy with stem cell support in relapsed or refractory Hodgkin lymphoma.
    Josting, A
    Rudolph, C
    Mapara, M
    Rueffer, U
    Von Schilling, C
    Doerken, B
    Diehl, V
    Engert, A
    BLOOD, 2000, 96 (11) : 240B - 240B
  • [45] The value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high-risk myelodysplastic syndromes and AML in elderly patients (vol 103, pg 2908, 2004)
    Ossenkoppele
    Schaafsma, MR
    Peters, GJ
    van der Holt, B
    Selleslag, D
    BLOOD, 2004, 104 (01) : 42 - 42
  • [46] Busulfan, Vp-16, cytarabine, and G-Csf as conditioning regimen for patients with acute myeloid leukemia undergoing autologous stem cell transplantation.: Preliminary results of Spanish PETHEMA study
    de la Rubia, J
    Díaz-Mediavilla, J
    Martín, G
    San Miguel, J
    Fernández, P
    Sayas, M
    Alcalá, A
    Bello, J
    Martin, Y
    Arias, J
    Martin, M
    Amador, J
    Pérez, C
    Sanz, M
    BONE MARROW TRANSPLANTATION, 2002, 29 : S75 - S75
  • [47] Blocking effect of G-CSF and z-VAD-fmk on apoptosis induced with ATRA in P39 cell line.
    Hassan, Z
    Forsblom, A
    Hellström-Lindberg, E
    BLOOD, 1998, 92 (10) : 419A - 419A
  • [48] MOBILIZATION OF PERIPHERAL-BLOOD PROGENITOR CELLS BY HIGH-DOSE ARA-C, VP-16 AND RECOMBINANT HUMAN GRANULOCYTE-COLONY-STIMULATING FACTOR - FACTORS AFFECTING PROGENITOR-CELL YIELDS
    SHIMAZAKI, C
    YAMAGATA, N
    TATSUMI, T
    HIRATA, T
    OKU, N
    ASHIHARA, E
    GOTO, H
    INABA, T
    FUJITA, N
    HARUYAMA, H
    NAKAGAWA, M
    BONE MARROW TRANSPLANTATION, 1995, 15 (05) : 763 - 767
  • [49] Intermediate VP-16 (1gr/m2) plus G-CSF (10mcg/kg) or cyclophosphamide (3gr/m2) plus G-CSF (10mcg/kg) for progenitor cell mobilisation in lymphoma patients
    Pivkova, A.
    Stavrik, S. Genadieva
    Stojanoski, Z.
    Cevreska, L.
    Karanfilski, O.
    Milenkov, V.
    Georgievski, B.
    BONE MARROW TRANSPLANTATION, 2009, 43 : S212 - S212
  • [50] High-dose busulfan (BU), VP-16, and ARA-C with peripheral blood progenitor cell (PBPC) support for patients with refractory and relapsed Hodgkins (HD) and non-Hodgkin's (NHL) lymphoma.
    Zimmerman, TM
    Grad, GI
    Grinblatt, DL
    Michelson, GC
    Williams, SF
    BLOOD, 1996, 88 (10) : 483 - 483
12345